Research / CRVL / Fundamental state Inspectable configuration
State dimensions Filing 0001193125-26-237024 Insurance
Cash 100th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.cash
$233.1M · CORE · VALID
Net-income growth 40th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.net_income
15.95% · CORE · VALID
Revenue growth 15th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.revenue
7.03% · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 28 states Self-history eligible
Sep 30, 2021 3/3 normalized Level 3 Dec 31, 2021 3/3 normalized Level 3 Mar 31, 2022 3/3 normalized Level 3 Jun 30, 2022 3/3 normalized Level 3 Sep 30, 2022 3/3 normalized Level 3 Dec 31, 2022 3/3 normalized Level 3 Mar 31, 2023 3/3 normalized Level 3 Jun 30, 2023 3/3 normalized Level 3 Sep 30, 2023 3/3 normalized Level 3 Dec 31, 2023 3/3 normalized Level 3 Mar 31, 2024 3/3 normalized Level 3 Jun 30, 2024 3/3 normalized Level 3 Sep 30, 2024 3/3 normalized Level 3 Dec 31, 2024 3/3 normalized Level 3 Mar 31, 2025 3/3 normalized Level 3 Jun 30, 2025 3/3 normalized Level 3 Sep 30, 2025 3/3 normalized Level 3 Dec 31, 2025 3/3 normalized Level 3 Mar 31, 2026 3/3 normalized Level 3 Jun 30, 2026 3/3 normalized Level 4 Period transition
What moved in the state? Cash Increased
Previous $230.0M
Current $233.1M
Delta $3.0M Earnings Growth Increased
Previous 1.70%
Current 15.95%
Delta 14.25% Revenue Growth Increased
Previous 3.36%
Current 7.03%
Delta 3.67% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.